Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Employee option grant covers 155,446 ADIL shares at $4.22 exercise price
- ➤Option carries a ten-year term and vests over four years
- ➤IND filing for AT177 planned for the first half of 2027
- ➤Phase 1a UC trial planned to commence in the second half of 2027
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.
The option award has an exercise price of $4.22 per share, the closing price of the Company’s common stock on September 25, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the recipient’s continued service through each applicable vesting date.
Get started
Create a free account to read the full story.